{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T04:33:05Z","timestamp":1773030785106,"version":"3.50.1"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"47","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1097\/md.0000000000008700","type":"journal-article","created":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T19:13:26Z","timestamp":1511378006000},"page":"e8700","source":"Crossref","is-referenced-by-count":7,"title":["Effect of MDR1 C1236T polymorphism on cyclosporine pharmacokinetics"],"prefix":"10.1097","volume":"96","author":[{"given":"Zhe","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunsong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhimei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ge","family":"Gui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-45-20210309","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.clpt.2004.01.009","article-title":"CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation","volume":"75","author":"Anglicheau","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"R2-45-20210309","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1742-7843.2008.00300.x","article-title":"Meta-analysis of the effect of MDR1 C3435T polymorphism on cyclosporine pharmacokinetics","volume":"103","author":"Jiang","year":"2008","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R3-45-20210309","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1034\/j.1600-6143.2002.20814.x","article-title":"Adequate early cyclosporine exposure is critical to prevent renal allograft rejection: patients monitored by absorption profiling","volume":"2","author":"Clase","year":"2002","journal-title":"Am J Transplant"},{"key":"R4-45-20210309","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00008571-200403000-00002","article-title":"The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients","volume":"14","author":"Haufroid","year":"2004","journal-title":"Pharmacogenetics"},{"key":"R5-45-20210309","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0300-483X(02)00297-4","article-title":"Genetically determined differences in P-glycoprotein function: implications for disease risk","volume":"181\u20132","author":"Fromm","year":"2002","journal-title":"Toxicology"},{"key":"R6-45-20210309","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00228-004-0879-0","article-title":"Single nucleotide polymorphisms of ABCB1 (MDR1) gene and distinct haplotype profile in a West Black African population","volume":"61","author":"Allabi","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"R7-45-20210309","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S1734-1140(11)70594-1","article-title":"Influence of ABCB1, CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients","volume":"63","author":"Qiu","year":"2011","journal-title":"Pharmacol Rep"},{"key":"R8-45-20210309","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1399-0012.2006.00635.x","article-title":"Multi-drug resistance gene-1 (MDR-1) haplotypes and the CYP3A5*1 genotype have no influence on ciclosporin dose requirements as assessed by C0 or C2 measurements","volume":"21","author":"Fredericks","year":"2007","journal-title":"Clin Transplant"},{"key":"R9-45-20210309","first-page":"141","article-title":"Influence of MDR1 genetic polymorphisms on ciclosporin pharmacokinetics in Chinese renal transplant patients","volume":"3","author":"Qiu","year":"2008","journal-title":"Chin J Clin Pharm"},{"key":"R10-45-20210309","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.arcmed.2008.06.008","article-title":"ABCB1 G2677 allele is associated with high dose requirement of cyclosporin A to prevent renal allograft rejection in North India","volume":"39","author":"Singh","year":"2008","journal-title":"Arch Med Res"},{"key":"R11-45-20210309","first-page":"265","article-title":"Relationship between multi-drug resistance gene polymorphism and blood concentration of cyclosporine in renal transplantation patients","volume":"5","author":"Fang","year":"2008","journal-title":"Chin J Clin Pharm"},{"key":"R12-45-20210309","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00228-008-0577-4","article-title":"Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem","volume":"65","author":"Wang","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"R13-45-20210309","first-page":"173","article-title":"Effect of ABCB1 genetic polymorphism on blood concentration of cyclosporine in renal transplantation patients","volume":"2","author":"Xin","year":"2013","journal-title":"China Pharmacist"},{"key":"R16-45-20210309","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1365-2125.2008.03180.x","article-title":"ABCB1 polymorphisms may have a minor effect on ciclosporin blood concentrations in myasthenia gravis patients","volume":"66","author":"Zhang","year":"2008","journal-title":"Brit J Clin Pharmacol"},{"key":"R17-45-20210309","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1126\/science.286.5439.487","article-title":"Pharmacogenomics: translating functional genomics into rational therapeutics","volume":"286","author":"Evans","year":"1999","journal-title":"Science"},{"key":"R18-45-20210309","first-page":"837","article-title":"Variations in bioavailability of cyclosporine and relationship to clinical outcome in renal transplant subpopulations","volume":"27","author":"Schroeder","year":"1995","journal-title":"Transplant Proc"},{"key":"R19-45-20210309","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00007890-199907150-00011","article-title":"Monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation","volume":"68","author":"Mahalati","year":"1999","journal-title":"Transplantation"},{"key":"R20-45-20210309","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0041-1345(03)00517-7","article-title":"Circadian variations in cyclosporine C2 concentrations during the first 2 weeks after liver transplantation","volume":"35","author":"Baraldo","year":"2003","journal-title":"Transplant Proc"},{"key":"R21-45-20210309","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2125.2005.02392.x","article-title":"Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression","volume":"60","author":"Chowbay","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"R22-45-20210309","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00008571-200302000-00005","article-title":"Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients","volume":"13","author":"Chowbay","year":"2003","journal-title":"Pharmacogenetics"},{"key":"R23-45-20210309","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.2146\/ajhp060080","article-title":"Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors","volume":"63","author":"Utecht","year":"2006","journal-title":"Am J Health Syst Pharm"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000008700","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:42:15Z","timestamp":1620960135000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201711270-00045"}},"subtitle":["A systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":21,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000008700","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]}}}